{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-041878","form_type":"8-K","ticker":"XAIR","cik":"0001641631","company_name":"Beyond Air, Inc.","filed_at":"2023-11-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.913138+00:00","generated_at":"2026-06-08T00:07:52.091110+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Beyond Air Q2 net loss widens to $16.2M; guides FY2025 revenue $12-$16M","bullets":["Revenue $0.24M vs $0 prior year; net loss $16.2M ($0.51 loss per share) vs $12.0M ($0.40) prior year.","Cash burn $16.5M ($10.1M ex one-time); cash & securities $43.9M as of Sept 30, 2023.","FY2025 revenue guidance $12M-$16M; submitted PMA supplement for cardiac surgery; CE Mark expected H1 2024.","Beyond Cancer presented positive first-in-human UNO data at SITC; VCAP trial underway, data mid-2024.","Agreement with Getz Healthcare for Asia-Pacific; Vizient Innovative Technology contract awarded."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-041878","json":"https://secwatch.observer/filing/0001493152-23-041878.json","markdown":"https://secwatch.observer/filing/0001493152-23-041878.md","text":"https://secwatch.observer/filing/0001493152-23-041878.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641631/000149315223041878/0001493152-23-041878-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641631/000149315223041878/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T00:07:52.091110+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"434511a4ad0d39dbc932a5c5014c01957edb8a40","claim":"Beyond Air, Inc. reported fiscal quarter ended September 30, 2023 results: revenue $0.24 million, net income ($16.2) million, EPS ($0.51) per share, basic and diluted.","evidence_excerpt":"first-in-human study for treatment of ASD in 2025 2 Financial Results for the Fiscal Quarter Ended September 30, 2023 Revenues for the three months ended September 30, 2023 were $0.24 million compared to zero for the quarter ended September 30, 2022. Cost of revenue of $0.4 million was recognized for the three months ended September 30, 2023, compared to $0.2 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641631/000149315223041878/0001493152-23-041878-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal quarter ended September 30, 2023"},{"label":"Revenue","value":"$0.24 million"},{"label":"Net income","value":"($16.2) million"},{"label":"EPS","value":"($0.51) per share, basic and diluted"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}